TL;DR
This study introduces a novel combined inflammation-based index, coNLR-PLR, to predict survival outcomes in colorectal cancer (CRC) patients undergoing adjuvant chemotherapy. The coNLR-PLR score effectively identifies patients with poorer prognoses, offering a simple yet powerful tool for clinical decision-making.
What Problem Does This Paper Address?
Colorectal cancer (CRC) remains a significant cause of cancer-related death, despite advancements in adjuvant chemotherapy. While inflammation is known to play a role in cancer progression and survival, predicting individual patient outcomes after chemotherapy remains challenging. Existing prognostic markers often rely on complex clinicopathological data. This paper addresses the need for simpler, more accurate biomarkers that can predict prognosis in CRC patients receiving adjuvant chemotherapy, specifically by exploring the combined predictive power of two inflammation-based indices: the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR).
Methods
The researchers conducted a retrospective analysis of 153 CRC patients who received palliative adjuvant chemotherapy. They calculated the NLR (absolute neutrophil count / absolute lymphocyte count) and PLR (absolute platelet count / absolute lymphocyte count) from baseline laboratory parameters. Using Receiver Operating Characteristic (ROC) curve analysis, they determined optimal cut-off values for NLR (2.24) and PLR (186). These values were used to categorize patients into "high" or "low" groups for each index. A combined score, coNLR-PLR, was then created: patients with both high NLR and high PLR received a score of 2, those with one high and one low received a score of 1, and those with both low received a score of 0. Survival analyses, including Overall Survival (OS) and Recurrence-Free Survival (RFS), were performed using the Kaplan-Meier method and analyzed with Cox proportional hazards models (univariate and multivariate).
Datasets
The study utilized a dataset of 153 colorectal cancer patients who underwent adjuvant chemotherapy at the Third People's Hospital of Hangzhou between January 2009 and January 2012. A comparison group of healthy controls was also included for baseline parameter comparisons. No new benchmarks were introduced; the study focused on analyzing existing patient data.
Key Insights and Ideas
- Inflammation as a Prognostic Indicator: The study reinforces the growing understanding that systemic inflammation, as reflected by blood cell ratios, is a critical factor influencing cancer prognosis.
- Synergistic Power of Combined Indices: While NLR and PLR individually show some predictive value, their combination into the coNLR-PLR score significantly enhances predictive accuracy. This suggests that a more comprehensive picture of the inflammatory state is captured by looking at both neutrophil and platelet responses relative to lymphocytes.
- Simplicity and Accessibility: The coNLR-PLR score is derived from readily available blood test results, making it a practical and easily implementable prognostic tool in clinical settings, unlike more complex clinicopathological models.
- Independent Prognostic Factor: The coNLR-PLR score emerged as a strong, independent predictor of both OS and RFS, meaning it provides prognostic information beyond other established factors.
Key Results
- The optimal cut-off values determined by ROC analysis were NLR = 2.24 and PLR = 186.
- Kaplan-Meier analysis revealed that patients with a high coNLR-PLR score had significantly poorer OS and RFS (P < .05).
- In both univariate and multivariate Cox proportional hazards analyses, the coNLR-PLR score was identified as a significant independent prognostic factor for OS and RFS (P < .05).
- Specifically, patients with a coNLR-PLR score of 2 had a significantly higher risk of recurrence (63.64%) and death (73.0%) compared to those with a score of 0 or 1.
Limitations and Future Work
The authors acknowledge several limitations:
- Retrospective Design: The study's retrospective nature introduces potential selection bias.
- Adverse Reaction Data: The study did not evaluate chemotherapy-related adverse reactions, which could influence patient quality of life and survival.
- Future Work: The authors suggest that further prospective studies are needed to validate these findings and to clarify whether the coNLR-PLR index can be incorporated into cancer patient stratification systems for personalized treatment strategies. They also highlight the need to explore the underlying mechanisms by which these inflammatory markers influence chemotherapy outcomes.
Summary updated